Form 8-K

8-K — Verastem, Inc.

Accession: 0001104659-26-074915

Filed: 2026-06-17

Period: 2026-06-16

CIK: 0001526119

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — tm2618108d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2618108d1_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2618108d1_8k.htm · Sequence: 1

false

0001526119

2026-06-16

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

June 16, 2026

Verastem,

Inc.

(Exact Name of Registrant as Specified in

Charter)

Delaware

001-35403

27-3269467

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

117 Kendrick Street, Suite 500, Needham, MA

02494

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including

area code: (781) 292-4200

(Former Name or Former Address, if Changed

Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under

the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under

the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under

the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under

the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common stock, $0.0001 par value per share

VSTM

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging

growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities

Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ¨

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for

complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01 Regulation FD Disclosure

On June 17, 2026, Verastem, Inc. (the “Company”)

issued a press release announcing positive updated results from RAMP 205 evaluating avutometinib plus defactinib in combination with standard-of-care

chemotherapy in first-line metastatic pancreatic ductal carcinoma (“mPDAC”).

A copy of this press release is furnished hereto as Exhibit 99.1

to this Current Report on Form 8-K.

Item 8.01 Other Events

Positive Updated Results from RAMP 205 Evaluating Avutometinib

Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer

On June 17, 2026, the Company announced positive updated safety and

efficacy results from the RAMP 205 Phase 1b/2a trial Recommended Phase 2 Dose (“RP2D”) cohort of 29 patients evaluating avutometinib

plus defactinib in combination with gemcitabine and nab-paclitaxel in first-line mPDAC.

In the Phase 1b/2a trial, 29 patients were enrolled and treated at

the RP2D with avutometinib 2.4 mg twice weekly, defactinib 200 mg twice daily for 3 weeks on and one week off, and gemcitabine (800 mg/m2)

plus nab-paclitaxel (125 mg/m2) administered on Days 1, 8, and 15 of each 28-day cycle. At diagnosis, 90% of patients presented with metastatic

disease. As of the June 5, 2026 data cutoff, with a median follow up of 9.8 months, the combination demonstrated clinical activity, including an 86% overall survival rate at 6 months. The progression-free survival rate at six months was 68%, and the confirmed objective

response rate was 52%. At the RP2D dose level, the majority (83%) of patients experienced tumor shrinkage. Nine patients remain

on treatment at this dose level. Adverse events remained generally consistent with the previously reported safety and tolerability profile,

with no new safety signals observed.

Dosing of First Patient in TARGET-D 201 Phase 2 Registration-Directed

Trial of VS-7375

On June 16, 2026, the Company also announced

that the first patient has been dosed in the TARGET-D 201 Phase 2 registration-directed trial evaluating VS-7375, an investigational oral

KRAS G12D (ON/OFF) inhibitor, to treat patients with KRAS G12D-mutated mPDAC.

TARGET-D 201 is a Phase 2, open-label, multi-center study to evaluate

VS-7375 at 900 mg daily both as monotherapy and in combination with full-dose cetuximab in patients with second-line mPDAC.

Item

9.01. Financial Statements and Exhibits

Exhibit No.

Description

99.1

Press Release, dated June 17, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,

the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VERASTEM, INC.

Dated: June 17, 2026

By:

/s/ Daniel W. Paterson

Daniel W. Paterson

President and Chief Executive

Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2618108d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Verastem Oncology Announces Positive Updated

Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic

Pancreatic Cancer

90% of patients in the study presented with

metastatic (Stage IV) disease at diagnosis

6-month overall survival rate was 86%; follow-up

continues and survival data continue to mature

BOSTON--(BUSINESS WIRE)—June 17, 2026--Verastem Oncology

(Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today

announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose (RP2D) cohort of 29 patients

evaluating avutometinib plus defactinib in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal

adenocarcinoma (PDAC).

KRAS is mutated in more than 90% of pancreatic cancers, making it a

key driver of tumor growth. The RAMP 205 trial was designed to evaluate whether simultaneous inhibition of KRAS-driven signaling and FAK-mediated

resistance pathways, in combination with standard-of-care chemotherapy, could improve outcomes for patients living with metastatic pancreatic

cancer.

“The updated data from the RAMP 205 trial provide important

clinical insights into the potential impact of combined RAF/MEK and FAK inhibition as a therapeutic option for pancreatic cancer.

While pancreatic cancer remains one of the most challenging cancers to treat, the early survival trends and deep

responses observed in this study indicate that avutometinib and defactinib are combinable with standard-of-care chemotherapy and

may help overcome resistance mechanisms inherent in pancreatic cancer and support further exploration of strategies designed to

address oncogenic signaling and mechanisms of treatment resistance,” said John Hayslip, M.D., chief medical officer at

Verastem Oncology. “We are grateful to PanCAN, the RAMP 205 investigators, and especially the patients and families who

participated in the trial.”

In the Phase 1b/2a study, 29 patients were enrolled and treated at the

RP2D with avutometinib 2.4 mg twice weekly (BIW), defactinib 200 mg twice daily (BID) for 3 weeks on and one week off, and

gemcitabine (800 mg/m2) plus nab-paclitaxel (125 mg/m2) administered on Days 1, 8, and 15 of each 28-day

cycle. At diagnosis, 90% of patients presented with metastatic disease. As of the June 5, 2026 data cutoff, with a median

follow up of 9.8 months, the combination demonstrated encouraging clinical activity, including an 86% overall survival (OS) rate at

6 months, with the OS data continuing to mature. The progression-free survival (PFS) rate at 6 months was 68%, and the confirmed

objective response rate (ORR) was 52% (15/29). At the RP2D dose, the majority (83%) of patients experienced tumor shrinkage. Nine

patients remain on treatment at this dose level. Adverse events remained generally consistent with the previously reported safety

and tolerability profile, with no new safety signals observed.

“For patients and their families facing a pancreatic cancer diagnosis,

every advance in research and understanding of the underlying biology driving this cancer matters,” said Anna Berkenblit, M.D.,

chief scientific and medical officer of the Pancreatic Cancer Action Network (PanCAN). “We awarded Verastem the PanCAN Therapeutic

Accelerator Award in 2022 to invest in research and development of novel treatment approaches. The results of the RAMP 205 trial underscore

the importance of continued research in the RAS/MAPK-pathway to help improve outcomes for patients living with pancreatic cancer.”

“We will continue to evaluate the potential role of avutometinib

plus defactinib in metastatic pancreatic cancer, including future development opportunities and potential strategic collaborations, informed

by the final overall survival results from the study as well as emerging data from VS-7375, our investigational potential best-in-class

oral KRAS G12D (ON/OFF) inhibitor, currently being evaluated in metastatic pancreatic cancer as both a monotherapy and in combination

regimens,” said Dan Paterson, president and chief executive officer of Verastem Oncology. “We will also assess opportunities

to share these data in the future, including at a medical meeting”.

In May 2022, Verastem Oncology was selected by PanCAN

to receive the inaugural PanCAN Therapeutic Accelerator Award, supporting evaluation of avutometinib in combination with defactinib in

front-line metastatic pancreatic cancer. Designed to accelerate the development of new pancreatic cancer treatments, the award provided

Verastem with $3.8M following a rigorous, competitive process involving scientific, business, and programmatic review from leading

experts in the field. In parallel, a working group led by PanCAN was formed as a partnership between Verastem and the academic community

to further understand the science behind and the potential of this investigational treatment combination to improve outcomes for patients.

About Metastatic Pancreatic Cancer

Pancreatic cancer is the third leading cause of cancer-related death

in the U.S. and seventh leading cause of cancer-associated mortality worldwide. Metastatic pancreatic cancer, or stage IV disease,

occurs when the cancer spreads beyond the pancreas to distant organs. More than 90% of pancreatic cancers harbor KRAS mutations, underscoring

the central role of KRAS in the development and the progression of the disease. Approximately 40% of pancreatic tumors harbor a KRAS G12D

mutation, the most prevalent subtype in pancreatic cancer. Patients with KRAS G12D-mutant tumors often have poorer outcomes, underscoring the

need for therapies designed specifically to inhibit this mutation potently and for a long duration. Each year, more than

30,000 people in the U.S. and over 240,000 people globally are diagnosed with metastatic pancreatic cancer. There has been minimal progress

with treatment, and the five-year survival rate remains approximately 3%. Current treatment approaches may include surgery, chemotherapy,

radiation therapy, targeted therapies, or a combination of these modalities.

About RAMP 205 Phase 1b/2a Study

RAMP 205 is a multicenter, open-label, single arm Phase 1b/2a study to evaluate the safety, tolerability, and efficacy of avutometinib and defactinib in combination with standard of care chemotherapy

(gemcitabine and nab-paclitaxel) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Part A of the

study evaluated varied dose and schedule combinations to determine the recommended Phase 2 dose for expansion into Part B. RAMP 205

is supported by a PanCAN Therapeutic Accelerator Award.

About AVMAPKI and FAKZYNJA Combination Therapy

AVMAPKI (avutometinib) inhibits MEK kinase activity while also blocking

the compensatory reactivation of MEK by upstream RAF. RAF and MEK proteins are regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. Blocking

RAF and/or MEK activates FAK, a key mediator of drug resistance. FAKZYNJA (defactinib) is a FAK inhibitor and together, the avutometinib

and defactinib combination was designed to provide a more complete blockade of the signaling that drives the growth and drug resistance

of RAS/MAPK pathway-dependent tumors.

The U.S. Food and Drug Administration (FDA) approved AVMAPKI® FAKZYNJA® CO-PACK

(avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent LGSOC who have received prior

systemic therapy on May 8, 2025. Continued approval for this indication may be contingent upon verification and description

of clinical benefit in a confirmatory trial. Verastem is conducting RAMP 301 (GOG-3097/ENGOT-ov81/GTG-UK) (NCT06072781), an

international Phase 3 confirmatory trial evaluating the combination of avutometinib and defactinib versus standard chemotherapy or hormonal

therapy for the treatment of recurrent low-grade serous ovarian cancer (LGSOC) with and without a KRAS mutation. Verastem is

also evaluating avutometinib plus defactinib with standard-of-care chemotherapy as a potential treatment in the first-line for patients

with advanced pancreatic cancer (RAMP 205; NCT05669482). Avutometinib and defactinib are not approved by the FDA or any other regulatory

authority, either in combination or with other therapies, for any of these investigative uses. Neither avutometinib nor defactinib are

approved by the FDA or any other regulatory authority on a stand-alone basis for any use.

AVMAPKI FAKZYNJA CO-PACK U.S. Indication

Indication

AVMAPKI FAKZYNJA CO-PACK is indicated for the treatment of adult patients

with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.

This indication is approved under accelerated approval based on tumor

response rate and duration of response. Continued approval for this indication may be contingent upon verification and description

of clinical benefit in a confirmatory trial.

Important Safety Information

Warnings and Precautions

· Ocular Toxicities: Ocular toxicities, including visual impairment

and vitreoretinal disorders, occurred. Perform comprehensive ophthalmic evaluation at baseline, prior to cycle 2, every three cycles thereafter,

and as clinically indicated. Withhold AVMAPKI FAKZYNJA CO-PACK for ocular toxicities until improvement at the same or reduced dose. Permanently

discontinue AVMAPKI FAKZYNJA CO-PACK for any grade 4 toxicity.

· Serious Skin Toxicities: Skin toxicities, including photosensitivity

and severe cutaneous adverse reactions (SCARSs) occurred. Adhere to concomitant medications. Monitor for skin toxicities and interrupt,

reduce or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity, tolerability and duration.

· Hepatotoxicity: Monitor liver function tests prior to each cycle,

on day 15 of the first 4 cycles, and as clinically indicated. Withhold, reduce or discontinue AVMAPKI FAKZYNJA CO-PACK based on severity

and persistence of abnormality.

· Rhabdomyolysis: Monitor creatine phosphokinase prior to the start

of each cycle, on day 15 of the first four cycles, and as clinically indicated. If increased CPK occurs, evaluate patients for rhabdomyolysis

or other causes. Withhold, reduce or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity and duration of the adverse reaction.

· Embryo-Fetal Toxicity: AVMAPKI FAKZYNJA CO-PACK can cause fetal

harm. Advise patients of the potential risk to a fetus and to use effective contraception.

Adverse Reactions

The most common (≥ 25%) adverse reactions, including laboratory

abnormalities, were increased creatine phosphokinase, nausea, fatigue, increased aspartate aminotransferase, rash, diarrhea, musculoskeletal

pain, edema, decreased hemoglobin, increased alanine aminotransferase, vomiting, increased blood bilirubin, increased triglycerides, decreased

lymphocyte count, abdominal pain, dyspepsia, dermatitis acneiform, vitreoretinal disorders, increased alkaline phosphatase, stomatitis,

pruritus, visual impairment, decreased platelet count, constipation, dry skin, dyspnea, cough, urinary tract infection, and decreased

neutrophil count.

Drug Interactions

· Strong and moderate CYP3A4 inhibitors: Avoid concomitant use with

AVMAPKI FAKZYNJA CO-PACK.

· Strong and moderate CYP3A4 inducers: Avoid concomitant use with AVMAPKI

FAKZYNJA CO-PACK.

· Warfarin: Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with

warfarin and use an alternative to warfarin.

· Gastric acid reducing agents: Avoid concomitant use of AVMAPKI FAKZYNJA

CO-PACK with proton pump inhibitors (PPIs) or H2 receptor antagonists. If use of an acid-reducing agent cannot be avoided, administer

FAKZYNJA 2 hours before or 2 hours after the administration of a locally acting antacid.

Use in Specific Populations

· Lactation: Advise not to breastfeed.

· Fertility: May impair fertility in males and females.

Click here for full Prescribing Information.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed

to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets

AVMAPKI® FAKZYNJA® CO-PACK in the U.S. Our pipeline is focused on novel small molecule

drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition,

FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.

Forward-Looking Statements

This press release includes forward-looking statements. These forward-looking

statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,”

“could,” “may,” “believe,” “estimate,” “forecast,” “goal,” “project,”

and other words of similar meaning. Such forward-looking statements address various matters about, among other things, Verastem Oncology’s

programs and product candidates, strategy, future plans and prospects, including statements related to the potential for and timing of

commercialization of product candidates, the expected outcome and benefits of the Company’s collaboration with GenFleet Therapeutics

(Shanghai), Inc., the timing of commencing and completing trials and compiling data, the expected timing of the presentation of data

by the Company and the potential clinical value of various of the Company’s clinical trials. Each forward-looking statement contained

in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed

or implied by such statement. Applicable risks and uncertainties include, among others: the uncertainties inherent in research and development,

such as the possibility of negative or unexpected results of clinical trials; that we may not see a return on investment on the payments

we have and may continue to make pursuant to the collaboration and option agreement with GenFleet, or that GenFleet may fail to fully

perform under the agreement; that we may not be successful in our continued commercialization of AVMAPKI FAKZYNJA CO-PACK; that the development

and commercialization of our product candidates may take longer or cost more than planned, including as a result of conducting additional

studies or our decisions regarding execution of such commercialization; that data may not be available when expected; risks associated

with preliminary and interim data, which may not be representative of more mature data; risks associated with the recent changes in administration

policy or actions that may create regulatory uncertainty that may adversely affect our business; risks associated with the current administration’s

reductions to the FDA’s workforce and any subsequent reductions that may lead to disruptions and delays in the FDA’s review

and oversight of our product candidates and impact the FDA’s ability to provide timely feedback on our development programs; that

our product candidates may not receive regulatory approval, become commercially successful products, or result in new treatment options

being offered to patients; and the risks identified under the heading "Risk Factors" as detailed in the Company’s Annual

Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission (SEC) on March 4,

2026, as well as the other information we file with the SEC, are possibly realized. We caution investors not to place considerable

reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC,

available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press

release speak only as of the date of this press release, and we undertake no obligation to update or revise any of these statements. Our

business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others

should give careful consideration to these risks and uncertainties.

For Investor and Media Inquiries:

Julissa Viana

Senior Vice President, Corporate Communications

Investor Relations and Patient Advocacy

investors@verastem.com or

media@verastem.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Jun. 16, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 16, 2026

Entity File Number

001-35403

Entity Registrant Name

Verastem,

Inc.

Entity Central Index Key

0001526119

Entity Tax Identification Number

27-3269467

Entity Incorporation, State or Country Code

Entity Address, Address Line One

117 Kendrick Street

Entity Address, Address Line Two

Suite 500

Entity Address, City or Town

Needham

Entity Address, State or Province

Entity Address, Postal Zip Code

02494

City Area Code

781

Local Phone Number

292-4200

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, $0.0001 par value per share

Trading Symbol

VSTM

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration